(Q36725446)

English

Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial

scientific article published on 29 September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

phase III clinical trial

0 references

stem cell transplantation

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

22

object named as

Sergio Giralt

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

David G. Maloney

23

object named as

David G Maloney

1 reference

Europe PubMed Central

15 August 2017

PMC publication ID

7

object named as

Joseph H Antin

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Edward A. Stadtmauer

4

object named as

Edward A Stadtmauer

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

11

object named as

Ginna Laport

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

author name string

Amrita Krishnan

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Marcelo C Pasquini

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Brent Logan

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

David H Vesole

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Edwin Alyea

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Raymond Comenzo

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Stacey Goodman

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Parameswaran Hari

10

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Muzaffar H Qazilbash

12

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Scott Rowley

13

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Firoozeh Sahebi

14

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

George Somlo

15

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Dan T Vogl

16

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Daniel Weisdorf

17

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Marian Ewell

18

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Juan Wu

19

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Nancy L Geller

20

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Mary M Horowitz

21

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Blood Marrow Transplant Clinical Trials Network (BMT CTN)

24

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

29 September 2011

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

12

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

13

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1195-1203

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3611089

30 September 2017

Use of biological assignment in hematopoietic stem cell transplantation clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3611089

30 September 2017

A comparison of allografting with autografting for newly diagnosed myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3611089

30 September 2017

International uniform response criteria for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3611089

30 September 2017

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3611089

30 September 2017

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3611089

30 September 2017

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3611089

28 June 2018

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3611089

5 September 2018

Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3611089

5 September 2018

Duration of survival in patients with myeloma treated with thalidomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3611089

5 September 2018

Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3611089

5 September 2018

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3611089

5 September 2018

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3611089

5 September 2018

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3611089

5 September 2018

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3611089

5 September 2018

Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3611089

5 September 2018

Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3611089

20 October 2018

Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/21962393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21962393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/21962393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21962393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://pubmed.ncbi.nlm.nih.gov/21962393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/21962393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21962393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21962393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blood and marrow transplant clinical trials network (BMT CTN): addressing unanswered questions

1 reference

https://pubmed.ncbi.nlm.nih.gov/21962393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21962393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970243-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70243-1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36725446&oldid=2102345479"